Company / SG&A Expense
Wave Life Sciences Ltd. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$75.3M
FY2025
5-year range
$42.5M / $75.3M
FY2021-FY2025
Trend
+27.6%
vs FY2024
Sector context
#128 of 213
Health Care
What the data says
At $75M, Wave Life Sciences Ltd.'s sg&a expense ranks #86 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $43M in FY2021 to $75M in FY2025.
Based on SEC 10-K filings.
$75M in FY2025 with a 5-year CAGR of +9.0%.
Increased from $51M to $75M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +17.8%
- 5-Year CAGR
- +9.0%
- 10-Year CAGR
- -
Sector benchmark
#86 of 213 in Health CareTop 40% of 213This company $75.3M Sector average $722.3M
▼
-89.6% below sector average
Key checks
Key Insights
- Wave Life Sciences Ltd.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +9.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 27.6% year-over-year.
- Ranks #128 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $75.3M | +27.6% |
| FY2024 | $59.0M | +15.1% |
| FY2023 | $51.3M | +11.3% |
| FY2022 | $46.1M | +8.5% |
| FY2021 | $42.5M | -13.0% |
| FY2020 | $48.9M | +81.2% |
| FY2019 | $27.0M | -31.7% |
| FY2018 | $39.5M | +46.5% |
| FY2017 | $27.0M | +68.7% |
| FY2016 | $16.0M | +867.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026